
Kjell Magne Tveit
- Professor; MD, PhD
- +47 23 02 78 30
Publications 2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124
Publications 2018
Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial
Ann Intern Med, 168 (11), 775-782
DOI 10.7326/M17-1441, PubMed 29710125
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151
Publications 2017
National intestinal screening will reduce the occurrence and mortality of intestinal cancer
Tidsskr. Nor. Laegeforen., 137 (21), 1664
Nasjonal tarmkreftscreening skal redusere forekomst og dødelighet av tarmkreft
Tidsskr Nor Laegeforen, 137 (21)
DOI 10.4045/tidsskr.17.0889, PubMed 29135165
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137
Publications 2016
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
Oncotarget, 7 (27), 41948-41958
DOI 10.18632/oncotarget.9632, PubMed 27248825
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
Oncotarget, 7 (37), 59441-59457
DOI 10.18632/oncotarget.11118, PubMed 27509063
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330
Publications 2015
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
Ann Surg, 261 (5), 956-60
DOI 10.1097/SLA.0000000000000786, PubMed 24950280
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
Pharmacogenomics J, 16 (3), 272-9
DOI 10.1038/tpj.2015.54, PubMed 26261061
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
Int J Cancer, 137 (10), 2470-7
DOI 10.1002/ijc.29476, PubMed 25664394
Publications 2014
Utilization of radiation therapy in Norway after the implementation of the national cancer plan--a national, population-based study
Int J Radiat Oncol Biol Phys, 90 (3), 707-14
DOI 10.1016/j.ijrobp.2014.06.059, PubMed 25160610
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395
A review of the evolution of systemic chemotherapy in the management of colorectal cancer
Clin Colorectal Cancer, 14 (1), 1-10
DOI 10.1016/j.clcc.2014.11.002, PubMed 25579803
A controlled cohort study of long-term income in colorectal cancer patients
Support Care Cancer, 22 (10), 2821-30
DOI 10.1007/s00520-014-2258-4, PubMed 24821364
Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial
JAMA, 312 (6), 606-15
DOI 10.1001/jama.2014.8266, PubMed 25117129
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368
Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: Does it work at all?
Acta Oncol, 53 (7), 865-76
DOI 10.3109/0284186X.2014.895037, PubMed 24678823
Publications 2013
A controlled cohort study of sickness absence and disability pension in colorectal cancer survivors
Acta Oncol, 53 (6), 735-43
DOI 10.3109/0284186X.2013.844354, PubMed 24345277
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
Mol Oncol, 8 (1), 59-67
DOI 10.1016/j.molonc.2013.09.001, PubMed 24119443
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914
Publications 2012
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
PLoS One, 7 (4), e34150
DOI 10.1371/journal.pone.0034150, PubMed 22529906
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843
KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
Expert Rev Mol Diagn, 12 (4), 327-8
DOI 10.1586/erm.12.29, PubMed 22616697
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
Br J Cancer, 107 (10), 1684-91
DOI 10.1038/bjc.2012.463, PubMed 23099809
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155
Publications 2011
The level of claudin-7 is reduced as an early event in colorectal carcinogenesis
BMC Cancer, 11, 65
DOI 10.1186/1471-2407-11-65, PubMed 21310043
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418
Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations
Diagn Mol Pathol, 20 (3), 158-65
DOI 10.1097/PDM.0b013e31820b49e2, PubMed 21817902
Publications 2010
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687
Sexual function in females after radiotherapy for rectal cancer
Acta Oncol, 49 (6), 826-32
DOI 10.3109/0284186X.2010.486411, PubMed 20615170
Publications 2009
Preoperative staging and treatment options in T1 rectal adenocarcinoma
Acta Oncol, 48 (3), 328-42
DOI 10.1080/02841860802657243, PubMed 19180365
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group
Acta Oncol, 48 (3), 368-76
DOI 10.1080/02841860902755244, PubMed 19242829
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
Br J Cancer, 101 (8), 1282-9
DOI 10.1038/sj.bjc.6605333, PubMed 19773751
[Use of radiotherapy in South-Eastern Norway Regional Health Authority]
Tidsskr Nor Laegeforen, 129 (24), 2602-5
DOI 10.4045/tidsskr.09.0331, PubMed 20029555
Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis
BMC Cancer, 9, 201
DOI 10.1186/1471-2407-9-201, PubMed 19555470
Collagen mRNA levels changes during colorectal cancer carcinogenesis
BMC Cancer, 9, 136
DOI 10.1186/1471-2407-9-136, PubMed 19422682
Publications 2008
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann Oncol, 19 (5), 909-14
DOI 10.1093/annonc/mdm588, PubMed 18209013
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil
Ann Oncol, 19 (6), 1154-9
DOI 10.1093/annonc/mdn002, PubMed 18281265
CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas
Anticancer Res, 28 (4C), 2289-95
PubMed 18751408
Publications 2007
[Radiotherapy of rectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3090-3
PubMed 18049501
[Colorectal cancer registry]
Tidsskr Nor Laegeforen, 127 (21), 2834-5
PubMed 17987076
Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma
BMC Cancer, 7, 192
DOI 10.1186/1471-2407-7-192, PubMed 17935612
Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas
BMC Cancer, 7, 228
DOI 10.1186/1471-2407-7-228, PubMed 18093316
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer
Acta Oncol, 46 (7), 982-8
DOI 10.1080/02841860701261568, PubMed 17917829
[Multimodal treatment in colorectal cancer]
Tidsskr Nor Laegeforen, 127 (23), 3055
PubMed 18049492
Publications 2006
[Tumour-modifying therapy]
Tidsskr Nor Laegeforen, 126 (5), 628-32
PubMed 16505877
Nationwide quality assurance of rectal cancer treatment
Colorectal Dis, 8 (3), 224-9
DOI 10.1111/j.1463-1318.2005.00924.x, PubMed 16466564
Publications 2005
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
Acta Oncol, 44 (8), 904-12
DOI 10.1080/02841860500355900, PubMed 16332600
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
Ann Oncol, 17 (2), 252-8
DOI 10.1093/annonc/mdj060, PubMed 16291583
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Ann Oncol, 16 Suppl 1, i20-1
DOI 10.1093/annonc/mdi827, PubMed 15888739
Publications 2004
Legal and Ethical Considerations: Group 4 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003
Endoscopy, 36 (4), 362-5
DOI 10.1055/s-2004-814289, PubMed 15057692
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
Br J Cancer, 91 (8), 1434-41
DOI 10.1038/sj.bjc.6602172, PubMed 15381932
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765
Publications 2003
Epidermal growth factor receptor inhibition induces trichomegaly
Acta Oncol, 42 (4), 345-6
DOI 10.1080/02841860310006038, PubMed 12899508
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/s0959-8049(02)00741-4, PubMed 12628837
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer
Ann Oncol, 14 (7), 1006-7
DOI 10.1093/annonc/mdg297, PubMed 12853337
Publications 2002
Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention)
Scand J Gastroenterol, 37 (5), 568-73
DOI 10.1080/00365520252903125, PubMed 12059059
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Ann Oncol, 13 (12), 1868-73
DOI 10.1093/annonc/mdf324, PubMed 12453854
BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system
Electrophoresis, 23 (24), 4085-91
DOI 10.1002/elps.200290025, PubMed 12481264
Liver metastases from colorectal cancer--more cures awaiting?
Acta Oncol, 41 (7-8), 578-81
PubMed 14651200
Tarmkreft: informasjon om tarmkreft for pasienter pårørende og andreinteresserte
In Kreftinfo, Den norske kreftforening, Oslo, 6/2002 (4. oppl.), 25 s.
BIBSYS 030466571
Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study
Radiother Oncol, 62 (2), 207-13
DOI 10.1016/s0167-8140(01)00486-8, PubMed 11937248
Publications 2001
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593
Publications 2000
Intra-operative irradiation (IORT) for primary advanced and recurrent rectal cancer. a need for randomised studies
Eur J Cancer, 36 (7), 868-74
DOI 10.1016/s0959-8049(00)00015-0, PubMed 10785591
Publications 1999
Kolorektalcancer og analcancer: en veiledning for leger
Gruppen, Oslo, 67 s.
BIBSYS 99162646x
Radiotherapy in rectal cancer
Acta Oncol, 38 (1), 5-6
DOI 10.1080/028418699431744, PubMed 10090683
Location of pelvic recurrence after 'curative' low anterior resection for rectal cancer
Eur J Surg Oncol, 25 (6), 590-4
DOI 10.1053/ejso.1999.0712, PubMed 10556005
Publications 1998
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
DOI 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X, PubMed 9482581
Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients
Clin Cancer Res, 4 (9), 2125-8
PubMed 9748129
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study
Br J Cancer, 78 (1), 14-20
DOI 10.1038/bjc.1998.435, PubMed 9662244
Type 1 protein tyrosine kinases in benign and malignant breast lesions
Histopathology, 33 (6), 514-21
DOI 10.1046/j.1365-2559.1998.00498.x, PubMed 9870145
Is there a standard adjuvant treatment for rectal cancer?
Eur J Cancer, 34 (12), 1827-35
DOI 10.1016/s0959-8049(98)00257-3, PubMed 10023302
Publications 1997
Screening for ESR mutations in breast and ovarian cancer patients
Hum Mutat, 9 (6), 531-6
DOI 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4, PubMed 9195227
[Cytostatic treatment by general practitioners?]
Tidsskr Nor Laegeforen, 117 (27), 3911-2
PubMed 9441412
[Adjuvant treatment in operable colonic and rectal cancer. A new possibility]
Tidsskr Nor Laegeforen, 117 (20), 2991-2
PubMed 9340862
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group
Br J Surg, 84 (8), 1130-5
DOI 10.1002/bjs.1800840827, PubMed 9278661
Combined modality treatment including intraoperative radiotherapy in locally advanced and recurrent rectal cancer
Radiother Oncol, 44 (3), 277-82
DOI 10.1016/s0167-8140(97)00070-4, PubMed 9380828
Combined modality treatment including IORT in locally advanced and recurrent rectal cancer: results from a prospective Norwegian study
Front Radiat Ther Oncol, 31, 221-3
DOI 10.1159/000061129, PubMed 9263827
Publications 1996
[Treatment of fixed, primarily non-resected rectal cancer. Recommendations from Norwegian Gastrointestinal Cancer Group]
Tidsskr Nor Laegeforen, 116 (3), 379-81
PubMed 8638268
[Chemotherapy in colorectal cancer. Recommendations of the Norwegian Gastrointestinal Cancer Group]
Tidsskr Nor Laegeforen, 116 (3), 357-60
PubMed 8638262
Evaluation of digitally guided fine needle aspiration cytology versus fine needle core biopsy for the diagnosis of recurrent rectal cancer
Int J Colorectal Dis, 11 (6), 272-5
DOI 10.1007/s003840050060, PubMed 9007621
Publications 1995
Field homogeneity of bevelled intraoperative electron beam cones: the influence of virtual focus surface distance
Med Dosim, 20 (2), 105-9
DOI 10.1016/0958-3947(95)00011-k, PubMed 7632342
Publications 1994
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
Hum Genet, 94 (6), 665-70
DOI 10.1007/BF00206961, PubMed 7989041
ESTROGEN-RECEPTOR (ESR) POLYMORPHISMS AND BREAST-CANCER SUSCEPTIBILITY
Hum. Genet., 94 (6), 665-670
Host markers and prognosis in recurrent rectal carcinomas treated with radiotherapy
Acta Oncol, 33 (4), 415-21
DOI 10.3109/02841869409098438, PubMed 8018375
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
DOI 10.1016/s0002-9378(94)70215-2, PubMed 8116701
Publications 1993
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712
Flow cytometric DNA analysis as prognostic factor in human breast carcinoma
Pathol Res Pract, 189 (4), 405-10
DOI 10.1016/S0344-0338(11)80327-4, PubMed 8351241
Postirradiation changes in the pelvic wall. Findings on MR
Acta Radiol, 34 (6), 573-6
PubMed 8240891
Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity
Oncology, 50 (1), 14-7
DOI 10.1159/000227140, PubMed 8421594
[Treatment of anal cancer]
Tidsskr Nor Laegeforen, 113 (28), 3452-3
PubMed 8273073
Publications 1992
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Genes Chromosomes Cancer, 4 (2), 113-21
DOI 10.1002/gcc.2870040203, PubMed 1373310
Radiation-induced fracture of the sacrum: findings on MR
AJR Am J Roentgenol, 159 (1), 227
DOI 10.2214/ajr.159.1.1609713, PubMed 1609713
Carcinoembryonic antigen in anal carcinoma
Acta Oncol, 31 (3), 333-5
DOI 10.3109/02841869209108181, PubMed 1622654
[Endocavitary radiotherapy of rectal cancer]
Tidsskr Nor Laegeforen, 112 (12), 1599-600
PubMed 1615515
Publications 1991
Colony formation in urinary bladder carcinoma. Relationship to DNA flow cytometry, stage and histopathology
Anticancer Res, 11 (2), 777-81
PubMed 2064333
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329
Diagnosis of anal carcinoma--doctor's finger still the best?
Oncology, 48 (5), 383-6
DOI 10.1159/000226964, PubMed 1745485
Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity
Cancer, 67 (10), 2462-6
DOI 10.1002/1097-0142(19910515)67:10<2462::aid-cncr2820671012>3.0.co;2-1, PubMed 2015547
[Anus cancer]
Tidsskr Nor Laegeforen, 111 (10), 1211
PubMed 2042124
Publications 1990
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
Br J Cancer, 62 (4), 585-90
DOI 10.1038/bjc.1990.334, PubMed 1977466
Computed tomography of the urinary bladder shortly after radiation therapy for rectal carcinoma
Acta Radiol, 31 (6), 585-8
PubMed 2278782
Benzylidene-glucose: no effect after all?
Am J Clin Oncol, 13 (2), 161-3
DOI 10.1097/00000421-199004000-00014, PubMed 2316482
Drug sensitivity testing of human breast cancer
Acta Oncol, 29 (3), 335-8
DOI 10.3109/02841869009090010, PubMed 2194534
Publications 1989
Colony forming ability of human breast carcinomas: lack of prognostic significance
Br J Cancer, 60 (2), 216-9
DOI 10.1038/bjc.1989.254, PubMed 2765368
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay
Anticancer Res, 9 (6), 1577-82
PubMed 2483300
Primary treatment of carcinoma of the anus by combined radiotherapy and chemotherapy
Scand J Gastroenterol, 24 (10), 1243-7
DOI 10.3109/00365528909090794, PubMed 2513640
Publications 1988
Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations
Eur J Clin Pharmacol, 34 (5), 517-9
DOI 10.1007/BF01046713, PubMed 3203714
Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens
Br J Cancer, 58 (1), 8-12
DOI 10.1038/bjc.1988.151, PubMed 3048354
An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay
Histol Histopathol, 3 (3), 269-74
PubMed 2980233
Predictive chemosensitivity testing in malignant melanoma: reliable methodology--ineffective drugs
Br J Cancer, 58 (6), 734-7
DOI 10.1038/bjc.1988.299, PubMed 3224078
Publications 1987
Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer
Acta Oncol, 26 (4), 289-93
DOI 10.3109/02841868709089977, PubMed 3500730
Publications 1985
Chemosensitivity measurements of human tumour cells by soft agar assays are influenced by the culture conditions
Br J Cancer, 51 (6), 843-52
DOI 10.1038/bjc.1985.130, PubMed 4005141
Survival curves after X-ray and heat treatments for melanoma cells derived directly from surgical specimens of tumours in man
Radiother Oncol, 4 (1), 33-44
DOI 10.1016/s0167-8140(85)80060-8, PubMed 4035001
Selection of tumour cell subpopulations occurs during cultivation of human tumours in soft agar. A DNA flow cytometric study
Br J Cancer, 52 (5), 701-5
DOI 10.1038/bjc.1985.246, PubMed 4063145
Publications 1984
Detection of cancer-related proteins by two-dimensional electrophoresis
Ann N Y Acad Sci, 428, 173-85
DOI 10.1111/j.1749-6632.1984.tb12294.x, PubMed 6588905
Multicellular spheroids grown directly from human tumour material
Int J Cancer, 34 (1), 21-6
DOI 10.1002/ijc.2910340105, PubMed 6746116
Publications 1983
Stability of cadmium resistance and metallothionein levels in vitro and in vivo
Toxicol Appl Pharmacol, 67 (2), 274-83
DOI 10.1016/0041-008x(83)90234-x, PubMed 6836582
Spontaneous alteration in growth rates of two human melanoma xenografts. Concurrent changes in chemosensitivity
Eur J Cancer Clin Oncol, 19 (8), 1175-8
DOI 10.1016/0277-5379(83)90046-9, PubMed 6684563
[Individualized drug therapy of cancer based on an in vitro test]
Tidsskr Nor Laegeforen, 103 (2), 113-6
PubMed 6845299
[Drug therapy of malignant melanoma based on a cell culture test]
Tidsskr Nor Laegeforen, 103 (2), 117-9
PubMed 6845300
Publications 1982
Studies of human melanoma cells cultivated in monolayer and in soft agar: the usefulness of in vitro tests for predicting clinical responses to cancerostatic agents
[s.n.], Oslo, Fl. pag.
BIBSYS 83500676x
Colony growth and chemosensitivity in vitro of human melanoma biopsies. Relationship to clinical parameters
Int J Cancer, 29 (5), 533-8
DOI 10.1002/ijc.2910290508, PubMed 7095899
Publications 1981
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas
Br J Cancer, 44 (4), 539-44
DOI 10.1038/bjc.1981.223, PubMed 7295510
The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas
Int J Cancer, 28 (4), 403-8
DOI 10.1002/ijc.2910280402, PubMed 7309286
Cultivation of human melanomas in soft agar. Factors influencing plating efficiency and chemosensitivity
Int J Cancer, 28 (3), 329-34
DOI 10.1002/ijc.2910280312, PubMed 7319675
Do cell lines in vitro reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts
Br J Cancer, 44 (6), 775-86
DOI 10.1038/bjc.1981.276, PubMed 7326190
Publications 1980
Human embryonal carcinoma grown in athymic mice and in vitro
Cancer Res, 40 (3), 949-53
PubMed 7471109
A human melanoma cell line established from xenograft in athymic mice
Br J Cancer, 41 (5), 724-33
DOI 10.1038/bjc.1980.134, PubMed 7426299
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity
Int J Cancer, 26 (6), 717-22
DOI 10.1002/ijc.2910260604, PubMed 7216540
Publications 1978
[Teratocarcinoma as a model system in studies of malignancy and differentiation]
Tidsskr Nor Laegeforen, 98 (22), 998-1001
PubMed 684708